triage - the end points and sample size of the validation phase are yet to be confirmed. But based on the announcement at end of May 23, the combined Stage 3 of the pre-validation phase and the whole validation stage were anticipated to last 6 months. This implies that the validation study will be shorter but probably more focused. Stage 3 (30 bleed patients) is underway so perhaps sometime in Qtr 3 or 4 for completion of the validation stage.
EMvision Research Notes, page-2252
-
- There are more pages in this discussion • 430 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.14 |
Change
0.120(5.94%) |
Mkt cap ! $183.0M | |||
| Open | High | Low | Value | Volume |
| $2.05 | $2.14 | $2.05 | $80.72K | 39.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2500 | $2.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.15 | 14500 | 2 |
View Market Depth
| Last trade - 15.57pm 13/09/2024 (20 minute delay) ? |
| EMV (ASX) Chart |